Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Solas

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Toxics|May 26, 2023
Transdermal Nicotine Poisoning: A Rare Case Report of Occupational ExposureJenny Becam, Edouard Martin, Gildas Pouradier, et al.
Clinical and Translational Science|February 16, 2026
How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19Inès Ben Ghezala, Nathan Peiffer-Smadja, Caroline Solas, et al.
Therapeutic Drug Monitoring|November 10, 2017
Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose MethotrexateNicolas Fabresse, Bénédicte Devictor, Christel Pissier, et al.
Antiviral Therapy|February 15, 2017
Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentrationSylvie Bregigeon, Caroline Solas, Olivia Faucher, et al.
Cancer Chemotherapy and Pharmacology|March 16, 2011
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseasesRomain Guilhaumou, Nicolas Simon, Sylvie Quaranta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 12, 2023
Validation of a non-targeted method devoted to identification and quantitation of toxicologically relevant compounds in plasma with HRMSJenny Becam, Anne-Laure Pelissier-Alicot, Natalia Doudka, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patientsCaroline Solas, Philippe Colson, Isabelle Ravaux, et al.
Antiviral Research|July 14, 2020
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infectionNicolas Venisse, Gilles Peytavin, Stephane Bouchet, et al.
Clinical Pharmacology and Therapeutics|May 1, 2020
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2Philippine Eloy, Caroline Solas, Franck Touret, et al.
Journal of Clinical Pharmacology|December 24, 2014
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrationsSandra Bodeau, Eric Nguyen-Khac, Caroline Solas, et al.
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Toxics|May 26, 2023
Transdermal Nicotine Poisoning: A Rare Case Report of Occupational ExposureJenny Becam, Edouard Martin, Gildas Pouradier, et al.
Clinical and Translational Science|February 16, 2026
How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19Inès Ben Ghezala, Nathan Peiffer-Smadja, Caroline Solas, et al.
Therapeutic Drug Monitoring|November 10, 2017
Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose MethotrexateNicolas Fabresse, Bénédicte Devictor, Christel Pissier, et al.
Antiviral Therapy|February 15, 2017
Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentrationSylvie Bregigeon, Caroline Solas, Olivia Faucher, et al.
Cancer Chemotherapy and Pharmacology|March 16, 2011
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseasesRomain Guilhaumou, Nicolas Simon, Sylvie Quaranta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 12, 2023
Validation of a non-targeted method devoted to identification and quantitation of toxicologically relevant compounds in plasma with HRMSJenny Becam, Anne-Laure Pelissier-Alicot, Natalia Doudka, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patientsCaroline Solas, Philippe Colson, Isabelle Ravaux, et al.
Antiviral Research|July 14, 2020
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infectionNicolas Venisse, Gilles Peytavin, Stephane Bouchet, et al.
Clinical Pharmacology and Therapeutics|May 1, 2020
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2Philippine Eloy, Caroline Solas, Franck Touret, et al.
Journal of Clinical Pharmacology|December 24, 2014
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrationsSandra Bodeau, Eric Nguyen-Khac, Caroline Solas, et al.
Pageof 13